Successful Alliances: Novartis and Idenix Share the Secrets of Success - Pharmaceutical Executive


Successful Alliances: Novartis and Idenix Share the Secrets of Success


Why did you decide to partner, and not merge?

EBELING: With alliances, it is imperative to have a jointly defined vision. But the cultures can be different, with varied but complementary strengths. The culture of a young start-up biotech company, such as Idenix, is a key component behind the company's accomplishments to date, and this, as well as the structure of our deal, is beneficial to both parties. I do not believe that a full merger would provide the same platform for building the business.

SOMMADOSSI: The unique structure of the Idenix-Novartis strategic alliance keeps in place all of the elements that have made Idenix successful thus far: our innovative and entrepreneurial culture, our expertise and focus on antiretrovirals, and the management team that executes our mission. It also has provided Idenix the opportunity to enter public markets to continue building our own infrastructure, to expand our research and development functions, and to establish commercial operations.

Because Novartis does not have to license a product until it reaches initiation of Phase III clinical trials, Idenix takes on the early discovery and clinical development risk. Once a product is licensed, Novartis' experience and financial support complement the later-stage requirements to rapidly bring the drug to market. This strategic alliance leverages the strengths of Idenix and Novartis to achieve a true win-win for both pharmaceutical companies. Ultimately, the patients are the benefactors of this relationship because it enables us to deliver these medicines more rapidly and on a more global scale than either party could on its own.


blog comments powered by Disqus

Source: Biopartnerships,
Click here